Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 7Dermatologic 5Lymphoid 4Thoracic 3Head & Neck 3Genitourinary 3Sarcoma 2Gynecologic 2Gastrointestinal 2CNS 2Breast 2Myeloid 1

Conditions

Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Neoplasms 1Melanoma 1Liver Neoplasms 1Leukemia 1Kidney Neoplasms 1Glioblastoma 1Esophageal Neoplasms 1Disease 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Bronchogenic 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Interleukin-15 × Breast × Clear all
NCT07410676 2026-02-18

EBNK-ST-001

Essen Biotech

Phase 1/2 Recruiting
83 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Bronchogenic, Disease, Esophageal Neoplasms, Glioblastoma, Kidney Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms

NCT03127098 2024-08-06

QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

NantCell, Inc.

Phase 1/2 Terminated
3 enrolled 6 charts
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡